BioAtla, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCAB research report →
Companywww.bioatla.com
BioAtla, Inc. , a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
- CEO
- Jay Short
- IPO
- 2020
- Employees
- 61
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $4.56M
- P/E
- -0.11
- P/S
- 2.28
- P/B
- -0.15
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 105.95%
- Op Margin
- -2524.95%
- Net Margin
- -2530.85%
- ROE
- 166.67%
- ROIC
- 477.89%
Growth & Income
- Revenue
- $2.00M · -81.82%
- Net Income
- $-59,607,000 · 14.57%
- EPS
- $-50.50 · 29.86%
- Op Income
- $-59,305,000
- FCF YoY
- 32.99%
Performance & Tape
- 52W High
- $71.50
- 52W Low
- $3.26
- 50D MA
- $5.85
- 200D MA
- $22.17
- Beta
- 0.79
- Avg Volume
- 38.88K
Get TickerSpark's AI analysis on BCAB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 26 | Sievers Eric | other | 240,000 |
| Mar 11, 26 | SHORT JAY M PHD | other | 430,000 |
| Mar 10, 26 | Vasquez Christian | other | 240,000 |
| Feb 28, 26 | SHORT JAY M PHD | other | 7,728 |
| Feb 28, 26 | Vasquez Christian | other | 1,802 |
| Feb 28, 26 | WALDRON RICHARD A | other | 2,729 |
| Feb 28, 26 | Sievers Eric | other | 3,140 |
| Nov 30, 25 | WALDRON RICHARD A | other | 2,371 |
| Nov 30, 25 | Sievers Eric | other | 2,729 |
| Nov 30, 25 | SHORT JAY M PHD | other | 6,347 |
Our BCAB Coverage
We haven't published any research on BCAB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCAB Report →